Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma

Chan, Alex; Doğan, Ahmet

doi:10.1016/j.path.2019.03.012

Cited by 16 publications

(19 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is notable that the IPI score system does not include the host tumor microenvironment (TME). The clinical outcome is dependent on many factors, including tumor histologic aggressiveness, immunologic status, and the tumor microenvironment, especially the immunosuppressive regulators [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

Wang

Jiang²,

et al. 2021

JCM

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are defined as negative regulators that suppress the immune response through a variety of mechanisms, which usually cluster in cancer, inflammation, and autoimmune diseases. This study aims to investigate the correlation between M-MDSCs and the clinical features of diffuse large B-cell lymphoma (DLBCL) patients, as well as the possible accumulation mechanism of M-MDSCs. The level of M-MDSCs is significantly increased in newly diagnosed and relapsed DLBCL patients. Regarding newly diagnosed DLBCL patients, the frequency of M-MDSCs is positively correlated with tumor progression and negatively correlated with overall survival (OS). More importantly, the level of M-MDSCs can be defined as a biomarker for a poor prognosis in DLBCL patients. Additionally, interleukin-35 (IL-35) mediates the accumulation of M-MDSCs in DLBCL patients. Anti-IL-35 treatment significantly reduces levels of M-MDSCs in Ly8 tumor-bearing mice. Thus, M-MDSCs are involved in the pathological process of DLBCL. Targeting M-MDSCs may be a promising therapeutic strategy for the treatment of DLBCL patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

Wang

Jiang²,

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…For patients with DLBCL, the presence of TP53 mutations, especially in the TP53 DNA-binding domains, is an independent negative prognostic factor for survival. 26 - 29 The methylation or mutation of the TP53 promoter, followed by the loss of an intact gene allele, is one proposed mechanism that may explain tumorigenesis and the malignant transformation of DLBCL. 30 TP53 gene mutations are present in approximately 20% to 25% of DLBCL cases.…”

Section: Discussionmentioning

confidence: 99%

A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene – A Case Report and Literature Review

Hwang

Aboulafia

2021

Clin Med�Insights�Blood�Disord

View full text Add to dashboard Cite

Despite representing 30% to 40% of newly diagnosed cases of adult non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL) rarely presents (1) in the leukemic phase (2) with dysregulation of the TP53 tumor suppressor gene and (3) an elevated serum lactic acid level. In this case report and literature review, we highlight this unfortunate triad of poor prognostic features associated with an aggressive and fatal clinical course in a 53-year-old man with recrudescent DLBCL. A leukemic presentation of de novo or relapsed DLBCL is rare and may be related to differential expressions of adhesion molecules on cell surfaces. In addition, TP53 gene mutations are present in approximately 20% to 25% of DLBCL cases and foreshadow worse clinical outcomes. Finally, an elevated serum lactic acid level in DLBCL that is not clearly associated with sepsis syndrome is a poor prognostic factor for survival and manifests as type B lactic acidosis through the Warburg effect.

show abstract

“…The negative prognostic impact of TP53 mutations in DLBCL has been reported in a number of studies ( 7 ). Mutation and copy loss of TP53 are independent negative prognostic factors in DLBCL ( 8 ), while recent studies indicated that the prognostic role should be validated when combined with other indexes ( 9 ). For instance, Dobashi et al found that TP53 mutations and TP53 deletions were confirmed to be poor prognostic factors for overall survival (OS) and progression-free survival (PFS) only when both aberrations co-existed ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Identification of Potential Prognosis-Related TP53 Mutation and BCL6-LPP Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases

Zhang

Liu

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPrimary pituitary lymphoma (PPL) is an extremely rare disease with poor prognosis. Although PPL has been shown to be different from classical primary central nervous system lymphoma because of the embryological origin of structures, individual and precise treatment of PPL remains unknown.MethodsA 61-year-old man and a 65-year-old woman both diagnosed with primary pituitary diffuse large B cell lymphoma underwent genetic analysis of cerebrospinal fluid and tumor tissue by next generation sequencing.ResultsIn the first case, partial remission was achieved following R²-MTX chemotherapy. In the other case with TP53 mutation and BCL6-LPP fusion, disease progressed although different chemotherapy regimens were given.ConclusionThe gene mutation of TP53 and BCL6 may be identified as a marker responsible for prognostic difference in patients with PPL. Genetic analysis may provide a novel approach for precise management and prognosis prediction.

show abstract

Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma

Cited by 16 publications

References 85 publications

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients

A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene – A Case Report and Literature Review

Case Report: Identification of Potential Prognosis-Related TP53 Mutation and BCL6-LPP Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases

Contact Info

Product

Resources

About